Phase 1 Study Showing COTI-2 Safe in Potentially Treating Advanced Ovarian and Other Cancers

Phase 1 Study Showing COTI-2 Safe in Potentially Treating Advanced Ovarian and Other Cancers
Initial data from an early clinical trial in patients with advanced ovarian and other cancers found a potential oral therapy, COTI-2, to be safe at varying doses, supporting a more advanced Phase 2 trial in these people, Critical Outcome Technologies announced. “We are encouraged to see these PK [pharmacokinetic] data from our Phase 1 trial in gynecological malignancies,”

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *